NCT02996214

Paclitaxel Liposome for Squamous Non-Small-cell Lung Cancer Study(LIPUSU)

A Multicenter, Randomized, Open-label, Parallel-group Study of Paclitaxel Liposome and Cisplatin Compared With Gemcitabine and Cisplatin as First-line Therapy in Advanced Squamous Non-Small-Cell Lung Cancer

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 536 (estimated)
• Sponsor: Nanjing Luye Sike Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to investigate the efficacy and the safety of paclitaxel liposome and cisplatin compared with gemcitabine and cisplatin as first-line therapy in advanced squamous non-small-cell lung cancer .

Detailed description

The purpose of this study is to investigate the efficacy and safety of paclitaxel liposome and cisplatin compared with gemcitabine and cisplatin as first-line therapy in advanced squamous non-small-cell lung cancer .

Conditions

• Squamous Non-small-cell Lung Cancer

Interventions

Type	Name	Description
DRUG	Paclitaxel Liposome	Paclitaxel liposome injection 175 mg/m\^2, given on day 1 of a 21-day cycle, for 4-6 cycles.
DRUG	Gemcitabine	Gemcitabine 1000 mg/m\^2, given on days 1 and 8 of a 21-day cycle, for 4-6 cycles.
DRUG	Cisplatin	Cisplatin 75 mg/m\^2, given on day 1 of a 21-day cycle, for 4-6 cycles.

Timeline

• Start date: 2016-11-01
• Primary completion: 2019-12-01
• Completion: 2020-06-01
• First posted: 2016-12-19
• Last updated: 2020-02-13